Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3270 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Eusa Pharma to acquire Cytogen

Under the terms of the all-cash merger agreement Cytogen shareholders will receive $0.62 per share, representing a 35% premium on the company’s share price. To meet the acquisition